Logo image of IMUX

IMMUNIC INC (IMUX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IMUX - US4525EP1011 - Common Stock

0.6615 USD
0 (-0.51%)
Last: 1/12/2026, 8:00:02 PM
0.6606 USD
0 (-0.14%)
After Hours: 1/12/2026, 8:00:02 PM
Fundamental Rating

2

IMUX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. IMUX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMUX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMUX has reported negative net income.
IMUX had a negative operating cash flow in the past year.
IMUX had negative earnings in each of the past 5 years.
IMUX had a negative operating cash flow in each of the past 5 years.
IMUX Yearly Net Income VS EBIT VS OCF VS FCFIMUX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

IMUX has a Return On Assets of -253.16%. This is amonst the worse of the industry: IMUX underperforms 90.34% of its industry peers.
IMUX's Return On Equity of -981.49% is on the low side compared to the rest of the industry. IMUX is outperformed by 79.17% of its industry peers.
Industry RankSector Rank
ROA -253.16%
ROE -981.49%
ROIC N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
IMUX Yearly ROA, ROE, ROICIMUX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMUX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMUX Yearly Profit, Operating, Gross MarginsIMUX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, IMUX has more shares outstanding
Compared to 5 years ago, IMUX has more shares outstanding
IMUX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMUX Yearly Shares OutstandingIMUX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IMUX Yearly Total Debt VS Total AssetsIMUX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -26.97, we must say that IMUX is in the distress zone and has some risk of bankruptcy.
IMUX has a worse Altman-Z score (-26.97) than 85.80% of its industry peers.
There is no outstanding debt for IMUX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.97
ROIC/WACCN/A
WACCN/A
IMUX Yearly LT Debt VS Equity VS FCFIMUX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

IMUX has a Current Ratio of 1.31. This is a normal value and indicates that IMUX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of IMUX (1.31) is worse than 82.58% of its industry peers.
IMUX has a Quick Ratio of 1.31. This is a normal value and indicates that IMUX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IMUX (1.31) is worse than 81.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.31
IMUX Yearly Current Assets VS Current LiabilitesIMUX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

IMUX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.52%, which is quite impressive.
EPS 1Y (TTM)32.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMUX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.97% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y36.69%
EPS Next 2Y27.48%
EPS Next 3Y15.44%
EPS Next 5Y16.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMUX Yearly Revenue VS EstimatesIMUX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
IMUX Yearly EPS VS EstimatesIMUX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMUX. In the last year negative earnings were reported.
Also next year IMUX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMUX Price Earnings VS Forward Price EarningsIMUX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMUX Per share dataIMUX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as IMUX's earnings are expected to grow with 15.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3Y15.44%

More info and screens

0

5. Dividend

5.1 Amount

IMUX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IMMUNIC INC

NASDAQ:IMUX (1/12/2026, 8:00:02 PM)

After market: 0.6606 0 (-0.14%)

0.6615

0 (-0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)02-19 2026-02-19/amc
Inst Owners37.78%
Inst Owner Change0%
Ins Owners1.05%
Ins Owner Change0%
Market Cap79.57M
Revenue(TTM)N/A
Net Income(TTM)-103.05M
Analysts85.33
Price Target5.48 (728.42%)
Short Float %4.8%
Short Ratio4.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.54%
Min EPS beat(2)-18.84%
Max EPS beat(2)23.91%
EPS beat(4)1
Avg EPS beat(4)-0.51%
Min EPS beat(4)-18.84%
Max EPS beat(4)23.91%
EPS beat(8)3
Avg EPS beat(8)-0.39%
EPS beat(12)4
Avg EPS beat(12)-10.15%
EPS beat(16)7
Avg EPS beat(16)-6.64%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-29.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.8%
EPS NY rev (1m)0%
EPS NY rev (3m)12.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.58
P/tB 7.58
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -253.16%
ROE -981.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.85%
ROA(5y)-121.12%
ROE(3y)-324.95%
ROE(5y)-215.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.31
Altman-Z -26.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)211.81%
Cap/Depr(5y)217.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.83%
EPS Next Y36.69%
EPS Next 2Y27.48%
EPS Next 3Y15.44%
EPS Next 5Y16.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.46%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNIC INC / IMUX FAQ

Can you provide the ChartMill fundamental rating for IMMUNIC INC?

ChartMill assigns a fundamental rating of 2 / 10 to IMUX.


Can you provide the valuation status for IMMUNIC INC?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNIC INC (IMUX). This can be considered as Overvalued.


Can you provide the profitability details for IMMUNIC INC?

IMMUNIC INC (IMUX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for IMMUNIC INC?

The Earnings per Share (EPS) of IMMUNIC INC (IMUX) is expected to grow by 36.69% in the next year.